カテゴリ： GlobalData, アメリカ, 企業調査

Merck & Co Inc (MRK)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Merck & Co Inc (MRK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014333
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：490
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Merck & Co Inc (Merck) focuses on the discovery, development, manufacture and commercialization of prescription pharmaceuticals, biologic therapies, vaccines and animal healthcare products. It offers prescription products for treating cardiovascular, cancer, immunology, infectious, respiratory and women’s diseases, diabetes and vaccines. The company provides animal health products including vaccines, poultry products, livestock products and aquaculture products. Merck sells pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers; and animal health products to veterinarians, distributors and animal producers. The company’s operations outside the US are conducted primarily through subsidiaries. It offers its products in US, Europe, Middle East and Africa, Asia Pacific, Japan, Latin America and other countries. Merck is known as MSD outside the US and Canada and is headquartered in Kenilworth, New Jersey, the US.

Merck & Co Inc (MRK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 11
List of Figures 16
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 17
Merck & Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 18
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 19
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 20
Merck & Co Inc, Medical Devices Deals, 2011 to YTD 2017 22
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 23
Merck & Co Inc, Pharmaceuticals & Healthcare, Deal Details 39
Asset Purchase 39
Hypermarcas To Sell Rights To Manufacture Medicines To MSD Brazil Investments For US$31 Million 39
Adolor Reacquires Rights Of ENTEREG From GlaxoSmithKline 40
Venture Financing 41
Grail Raises USD914 Million in First Tranche of Series B Financing 41
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 43
Just Biotherapeutics Raises USD15 Million in Series A Financing Round 45
RaNA Therapeutics Raises USD55 Million in series B Financing 46
Afferent Pharma Raises USD55 Million in Series C Financing 47
Gladius Pharma Raises USD3.3 Million in Series A Financing 48
NGM Biopharma Raises USD106 Million in Series E Financing 49
EnGene Raises USD11 Million in Series B Venture Financing 50
OsteoQC Raises Funds in Venture Financing 51
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 52
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 53
OncoEthix Raises US$19 Million In Series B Financing 54
Aviir Raises US$20 Million In Venture Financing 56
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding Round 58
cCAM Biotherapeutics Raises US$6 Million In Series A Financing 59
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding 60
Aviir Secures US$10 Million In Venture Financing 61
High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 62
BeiGene Receives Investment From Merck Sharp & Dohme 63
HTG Molecular Raises USD15.7 Million in First Tranche of Series D Financing 64
Partnerships 65
Antigen Express Enters into Agreement with Merck for KEYTRUDA 65
CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 66
Aeglea BioTherapeutics Enters into Agreement with Merck 67
SELLAS Life Sciences Enters into Clinical Trial Agreement with Merck 68
Eisai Enters into Agreement with Merck for Eribulin 69
Eisai Enters into Agreement with Merck 70
AstraZeneca Enters into Agreement with Merck 71
Invenra Enters into Agreement With Merck 72
PDS Biotech Enters into Agreement with Merck 73
Leap Therapeutics Enters into Agreement with Merck International 74
Aduro Biotech Expands Agreement with Merck 75
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 76
Array BioPharma Enters into Agreement with Merck 77
Atara Biotherapeutics Enters into Agreement with Merck 78
HitGen Enters into Agreement with Merck 79
BerGenBio Enters into Agreement with Merck 80
Stratophase Enters into Agreement with Merck 81
CMIC Enters into Agreement with MSD for Diazoxide 82
Ramot at Tel Aviv University Enters into Research Agreement with Merck 83
NOXXON Pharma Enters into Agreement with Merck 84
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 85
Proteros biostructures Enters into Agreement with Merck Sharp & Dohme 86
Genexine Enters into Clinical Research Agreement with Merck 87
Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 88
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 89
Merck Enters into Distribution Agreement with JenKem Tech 90
MSD Enters into Agreement with Kyorin Pharma 91
Agency for Science, Technology and Research Enters into Agreement with Merck 92
Menarini Asia-Pacific Enters into Agreement with Merck 93
Innovative Targeting Solutions Enters into Research Agreement with Merck 94
Fujifilm Diosynth Biotech Partners with Merck 95
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 96
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 97
Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 98
ImmunoGen Enters into Research Agreement with Merck 99
Merck Enters into Agreement with AbCellera Biologics 100
Affimed Enters into Research Agreement with Merck 101
BioLineRx Enters into Agreement with Merck 102
Quartet Medicine Enters into Agreement with Merck 103
Complix Expands Agreement with Merck 104
Eli Lilly Expands its Agreement with Merck 105
Merck Enters into Agreement with Akeso Biopharma 106
Amgen and Merck Enter into Agreement 107
Viralytics Enters into Agreement with Merck 108
GlaxoSmithKline Partners with Merck 109
Synthace Enters into Agreement with Merck 110
MacroGenics Enters into Agreement with Merck 111
Incyte Extends Partnership with Merck 112
Proteros Enters Into an Agreement with Merck Sharp and Dohme 113
Merck Enters into Agreement with OBI Pharma 114
Merck Enters into Agreement with DNAtrix 115
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 116
Immune Design Enters into Clinical Collaboration Agreement with Merck 117
Laboratorios Farmaceuticos Rovi Enters into Co-Marketing Agreement with Merck Sharp & Dohme for Orvatez 118
Plexxikon Enters into Agreement with Merck 119
PeptiDream Enters into Peptide Discovery Agreement with Merck 120
Organovo Enters into Research Agreement with Merck Sharp & Dohme 121
Astellas Pharma to Enter into Agreement with MSD 122
Syndax Pharma Expands its Agreement with Merck 123
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 124
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 125
Merck Expands Agreement with Eli Lilly 126
Enumeral Biomedical Amends its Agreement with Merck Sharp & Dohme 127
Kyorin Pharma Amends Co-Marketing Agreement with MSD 128
Bind Therapeutics Enters into R&D Agreement with Merck 129
Advaxis Enters into Agreement with Merck 130
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 131
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 132
Merck Enters Into Co-Development Agreement With Samsung Bioepis For MK-1293 133
Dako Enters Into Co-Development Agreement With Merck 134
Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 135
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 136
Optimer Pharma Extends Co-Promotion Agreement With Cubist Pharma For Dificid 138
Abide Therapeutics Enters Into Co-Development Agreement With Merck 139
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 140
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 141
Merck And Samsung Bioepis Enter Biosimilars Development Agreement 142
Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 143
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 144
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 145
ActoGeniX Enters Into Research Agreement With Merck 146
TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 147
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 148
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 149
Redbiotec Extends Drug Discovery Agreement With Merck 151
Merck Forms Joint Venture With Supera Farma Laboratorios 152
MSD Enters Into Distribution Agreement With Julphar 153
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 154
Fundacion Medina Enters Into Research Agreement With Cubist Pharma 155
Chongqing Zhifei Biological Products Extends Co-Marketing Agreement With Merck For RotaTeq 156
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 157
Merck Enters Into Co-Development Agreement With Endocyte For Cancer Drug 158
MSD India Plans Co-Marketing Agreement For Diabetes Drugs 160
Ezose Sciences Enters Into Co-Development Agreement With Merck 161
Vaccine & Gene Therapy Institute Enters Research Agreement With Merck 162
Redbiotec Enters Into Drug Discovery Agreement With Merck 163
Merck Enters Into Co-Development Agreement With Beijing Genomics Institute 164
Merck Enters Into Co-Development Agreement With Serum Institute of India 165
Merck Extends Co-Promotion Agreement With Roche For VICTRELIS 166
Merck Enters Into Co-Promotion Agreement With Daewoong Pharma For Vytorin 167
MSD Enters Into Co-Marketing Agreement With Taiho Pharma For Vorinostat 168
Trius Therapeutics Enters into Agreement with Lawrence Livermore National Laboratory 169
MSD In India Enters Into Co-Marketing Agreement With Sun Pharma 170
Merck Amends Distribution Agreement With Johnson & Johnson 171
International Drug Development Institute Partners with Sanofi Pasteur 173
Optimer Pharma Enters Into Co-Promotion Agreement With Cubist Pharma 174
TPP Global Development Enters Into Agreement With University of Aberdeen 175
ARIAD Announces Co-Promotion Agreement With Merck 176
Lycera Enters Into Research Agreement With Merck 177
Merck Enters Into An Agreement With PAREXEL International 178
Licensing Agreements 179
Merck Enters into Licensing Agreement with Cue Biopharma 179
Merck Enters into Licensing And Option Agreement with AIMM Therapeutics 180
Urovant Sciences Enters into Licensing Agreement with Merck Sharp & Dohme 181
Merck Enters into Licensing Agreement with Teijin Pharma 182
Kyorin Pharma Enters into Licensing Agreement with Merck 183
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 184
Merck Enters into Licensing Agreement with Cancer Research Technology 185
Adimab Enters into Licensing Agreement with Merck 186
Merck Enters into Licensing Agreement with Selvita 187
Allergan Enters into Licensing Agreement with Merck 188
Merck Enters into Licensing Agreement with BioNovion 189
Zymeworks Extends Licensing Agreement with Merck 190
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 191
ARMO Biosciences Enters into Licensing Agreement with Merck 192
Cerecor Enters Into Licensing Agreement With Merck For MK-0657 193
Merck Enters into Licensing Agreement with Ra Pharma 195
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 197
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 199
Exelixis Enters Into Licensing Agreement With Merck For PI3K-delta 200
Zymeworks Enters into Licensing Agreement with Merck 201
Merck Enters into Licensing Agreement with Moderna Therapeutics 202
Merck Enters into Licensing Agreement with Harvard University 203
Merck Enters into Licensing Agreement with AureoGen Biosciences 204
Merck Enters into Licensing Agreement with Codexis for CodeEvolver Platform Technology 205
Merck Extends Licensing Agreement with Agenus 207
Arvinas Enters into Licensing Agreement with Merck 208
Merck Enters into Licensing Agreement with Medicines Patent Pool 209
Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 210
EnWave Enters into Licensing Agreement with Merck 212
Merck Enters into Licensing Agreement with NewLink Genetics 213
Euroscreen Enters into Licensing Agreement with Merck 215
Sun Pharma Enters into Licensing Agreement with Merck 216
Kyorin Pharma Enters into Licensing Agreement with Merck 217
Bionomics Enters into Licensing Agreement with Merck for BNC375 218
Gulf Pharma Enters into Licensing Agreement with MSD 219
NanoBio Enters Into Licensing Agreement With Merck 220
Nuevolution Enters Into Licensing Agreement With Merck 221
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 222
Merck Expands Licensing Agreement with Ablynx 224
Polyplus-transfection Enters Into Licensing Agreement With Merck 226
AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 227
Depomed Expands Licensing Agreement With Merck For Metformin Patents 229
Bionomics Extends Licensing Agreement with Merck 230
Merck Enters Into Licensing Agreement With Lupin 231
Xencor Enters Into Licensing Agreement With Merck 232
Merck Exercises Option For Licensing Agreement With Xenon Pharma For Cardiovascular Disease Targeted Compounds 233
Hawaii Biotech Enters Into Licensing Agreement With Merck For West Nile Vaccine Technology 234
Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 235
Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 236
Microbiotix Enters Into Licensing Agreement With Merck For MBX-700 And MBX-701 238
Menlo Therapeutics Enters into Licensing Agreement with Merck 239
Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 240
Netherlands Translational Research Center Enters Into Licensing Agreement With Merck 241
Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 242
Delphi Genetics Enters Into Licensing Agreement With Merck For StabyExpress Technology 243
MultiVir Enters into Licensing Agreement with Merck Sharp & Dohme 244
Merck Enters Into Licensing Agreement With Yamasa For EFdA 245
R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 246
Ambrx Enters Into Licensing Agreement With Merck For Site Specific Protein Medicinal Chemistry Technology 247
OncoEthix Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For OTX015 248
Merck Enters Into Licensing Agreement With Numerate For In Silico Drug Design Technology 249
Merck Extends Licensing Agreement with Codexis 250
Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 251
Mochida Pharma Enters Into Licensing Agreement With Merck 252
Bend Research Enters Into Licensing Agreement With Merck 253
Hawaii Biotech Enters Into Licensing Agreement With Merck 254
Merck Enters Into Licensing Agreement With FKD Therapies 255
AbD Serotec Amends Licensing Agreement With Merck 256
Trius Therapeutics Enters Into Licensing Agreement With Bayer HealthCare For Torezolid Phosphate 257
MSD Enters Into Licensing Agreement With Astellas US For vernakalant 258
Hanwha Chemical Enters Into Licensing Agreement With Merck For HD203 259
Hanmi Pharma Expands Licensing Agreement With Merck For Amosartan 260
Equity Offering 261
Bionomics Raises USD9 Million in Private Placement of Shares 261
OpGen Raises USD5 Million in Private Placement of Shares 262
BeiGene Raises USD97.4 Million in Private Placement of Series A-2 Preferred Stock 263
Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 264
BeiGene Raises USD74.5 Million in Private Placement of Series A Preferred Stock 265
Trius Therapeutics Completes Public Offering Of Shares For US$34 Million 266
Trius Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$5 Million 267
VirtualScopics Completes First Tranche Of Private Placement Of Shares For US$3 Million 269
Trius Therapeutics Completes Over-allotment Option Of Underwritten Public Offering For US$52 Million 270
Trius Therapeutics Completes Private Placement Of Units For US$30 Million 272
Debt Offering 273
Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 273
Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 274
Merck Completes Public Offering of Notes Due 2020 for USD1.25 Billion 275
Merck Completes Public Offering of Notes Due 2022 for USD1.25 Billion 277
Merck Completes Public Offering of Notes Due 2020 for USD700 Million 279
Merck Completes Public Offering of Notes Due 2025 for USD2.5 Billion 281
Merck Completes Public Offering of Notes Due 2017 for USD300 Million 283
Merck Completes Public Offering of Notes Due 2045 for USD2 Billion 285
Merck Raises USD1.25 Billion in Public Offering of 1.875% Notes Due 2026 287
Merck Raises USD625 Million in Public Offering of 2.5% Notes Due 2034 289
Merck Raises USD1.25 Billion in Public Offering of 1.125% Notes Due 2021 291
Cubist Pharma Completes Private Placement Of Notes Due 2020 For US$450 Million 293
Cubist Pharma Completes Private Placement Of Notes Due 2018 For US$350 Million 294
Merck Completes Public Offering Of Notes Due 2016 For US$500 Million 295
Merck Completes Public Offering Of Notes Due 2016 For US$1 Billion 297
Merck Completes Public Offering Of Notes Due 2018 For US$1 Billion 299
Merck Completes Public Offering Of Notes Due 2023 For US$1.75 Billion 301
Merck Completes Public Offering Of Notes Due 2043 For US$1.25 Billion 303
Merck Completes Public Offering Of Floating Notes Due 2018 For US$1 Billion 305
BeiGene Raises USD3 Million in Private Placement of Notes 307
Merck Completes Public Offering Of Notes Due 2042 For US$500 Million 308
Merck Completes Public Offering Of 1.1% Notes Due 2018 For US$1 Billion 310
Merck Completes Public Offering Of Notes Due 2022 For US$1 Billion 312
Asset Transactions 314
Pharmaron Acquires Hoddesdon UK Site from Merck Sharpe & Dohme 314
Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 315
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 316
Piramal Enterprises Acquires Five OTC Brands from Organon India and MSD for USD14 Million 317
Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 318
Merial to Acquire Manufacturing Facility from Merck 319
Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck 320
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 322
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 324
KBI Biopharma To Acquire Biologics Operations Of Merck 326
Amphastar Pharmaceuticals Acquires API manufacturing business of Merck 327
Oak Pharma Acquires Tafluprost Business from Merck 328
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 329
Aspen Acquires Portfolio of Drugs from Merck for USD600 Million 330
Forest Labs To Acquire US Marketing Rights To Saphris From Merck Sharp & Dohme For US$240 Million 333
CCS Healthcare To Acquire Propyless From Merck Sharp & Dohme 334
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 335
Cerecor Acquires Rights To COMT Inhibitors From Merck 336
Kyorin Acquires Production Facility from MSD 338
Acquisition 339
Merck Acquires Rigontec 339
Paratek Pharma May Sell Itself 341
Merck Acquires Afferent Pharma 343
Merck Acquires IOmet Pharma 344
Merck Acquires cCAM Biotherapeutics 345
Merck Acquires Cubist Pharma for USD9.5 Billion 346
Merck Acquires OncoEthix for USD375 Million 348
Merck Completes Acquisition of Idenix Pharma for USD3.9 Billion in cash 349
Alnylam Pharma Acquires Sirna Therapeutics From Merck 351
Akorn Acquires Inspire Pharma From Merck For US$53 Million 353
Cubist Pharma Completes Acquisition Of Optimer Pharma For Up To US$801 Million 355
Cubist Pharma Completes Acquisition Of Trius Therapeutics For Up To US$818 Million In A Tender Offer 357
Telerx Acquires Sentrx Safety Solutions, Pharmacovigilance Outsourcing Company 359
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 360
Merck Plans To Acquire Micro Labs, Maker Of Generic Drugs 362
Cubist Pharma Completes Acquisition Of Adolor For US$415 Million 363
Johnson & Johnson Acquires Johnson & Johnson Merck Consumer Pharma From Merck Sharp & Dohme For US$175 Million 365
Nuvisan Acquires Essex Pharma Development From Merck 366
Merck Completes Acquisition Of Inspire Pharma 367
Fujifilm Completes Acquisition Of MSD Biologics 369
Fujifilm Completes Acquisition Of Diosynth 371
Merck & Co Inc – Key Competitors 372
Merck & Co Inc – Key Employees 373
Merck & Co Inc – Locations And Subsidiaries 375
Head Office 375
Other Locations & Subsidiaries 375
Joint Venture 397
Recent Developments 399
Strategy And Business Planning 399
Jul 17, 2017: Governor Abbott Announces Merck IT Hub In Austin 399
Mar 02, 2017: Allergopharma Opens new Biopharmaceutical Production in Reinbek 400
Jan 13, 2016: BioMed X – Merck collaboration in the field of selective kinase inhibitors reaches major milestone 401
Financial Announcements 402
Oct 27, 2017: Merck Announces Third-Quarter 2017 Financial Results 402
Jul 28, 2017: Merck Announces Second-Quarter 2017 Financial Results 405
May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 408
Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 410
Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 412
May 05, 2016: Merck Announces First-Quarter 2016 Financial Results 415
Feb 03, 2016: Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results 417
Corporate Communications 420
Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 420
Mar 07, 2017: Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients 421
May 23, 2016: Merck Foundation Announces the Alliance to Advance Patient-Centered Cancer Care, a $15 Million Initiative to Improve Access to High-Quality Cancer Care in Underserved Communities in the United States 422
Mar 07, 2016: Merck Names Sanat Chattopadhyay President of Merck Manufacturing Division; Will Succeed Willie A. Deese Who Will Retire 423
Mar 04, 2016: Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa 424
Legal and Regulatory 425
Feb 15, 2017: Merck’s Wholly Owned Subsidiary Idenix Pharmaceuticals Awarded $2.54 Billion for Infringement of a Hepatitis C Drug Patent 425
Dec 16, 2016: Merck’s subsidiary wins $2.5bn patent verdict against Gilead Sciences 426
Mar 22, 2016: Ionis Pharmaceuticals and Merck Receive Positive Verdict on Gilead HCV Drug Patent Case 427
Jan 15, 2016: Merck Sues Merck for Improper Use of “Merck” 428
Government and Public Interest 429
Oct 19, 2017: Merck Foundation Launches Five-Year Initiative to Improve Diabetes Care for Vulnerable and Underserved U.S. Communities 429
Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 430
Feb 09, 2017: Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care 431
Jan 19, 2017: MSD for Mothers Commits $10 Million and Business Expertise to the Global Financing Facility to Help End Preventable Deaths of Mothers 432
Jan 18, 2017: Merck Foundation Grant Expands Project ECHO in Vietnam and India 433
Sep 29, 2016: Merck Foundation Grant Expands YMCA’s Diabetes Prevention Program in Five States 434
Jun 06, 2016: GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com 435
Mar 24, 2016: Merck Foundation Awards Grant to American Cancer Society for Program to Improve Access to High-Quality Cancer Care in Underserved Communities 437
Product News 438
12/28/2016: AHF lauds the research community on an experimental Ebola vaccine that showed 100% efficacy in a clinical trial 438
12/22/2016: Final Trial Results Confirm Ebola Vaccine Provides High Protection Against Disease 439
10/26/2016: Merck Highlights Data Presentation on ZERBAXA at ID Week 2016 441
Sep 27, 2016: IDH and CIC Mutations Provide Prognostic Information for Grade II and III Gliomas 442
09/05/2016: Hypertension: releasing the pressure at its source 443
Jul 18, 2016: Publication of HPTN 052 final results 445
06/16/2016: Cempra to Host Analyst and Investor Day on June 23, 2016 446
06/10/2016: Cempra Announces Solithromycin Presentations at ASM Microbe 2016 Conference 447
05/30/2017: Merck Highlights Data on ZERBAXA at ASM Microbe 2017 448
04/19/2017: Merck to Present Data on Relebactam at ECCMID 2017 449
04/19/2017: Merck to Present Data on ZERBAXA at ECCMID 2017 450
04/07/2016: Merck To Present Data on ZERBAXA at ECCMID 2016 451
02/22/2016: New Antibiotic Against Drug-Resistant Bacteria Now Available 452
02/05/2016: The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra Oral Solithromycin in Community-Acquired Bacterial Pneumonia 453
Product Approvals 454
Jul 25, 2016: Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920) 454
Jul 05, 2016: Cempra Announces FDA Acceptance of Solithera New Drug Applications in the Treatment of Community-Acquired Bacterial Pneumonia 455
Jun 28, 2016: Cempra Submits Marketing Authorization Application to EMA for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia 456
May 01, 2016: Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia 457
Mar 18, 2016: ONO Receives Approval for PROEMEND for Intravenous Infusion 150 mg for Treatment of Chemotherapy-Induced Nausea and Vomiting for a Partial Change in Approved Items for Additional Application to Pediatric Patients 458
Feb 04, 2016: FDA Approves Merck’s Single-Dose EMEND (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy 459
Clinical Trials 460
Jul 25, 2017: Merck’s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection 460
Jul 06, 2017: Merck Announces Presentation on Doravirine at IAS 2017 462
Feb 14, 2017: Merck’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial 463
Dec 05, 2016: Aduro Biotech Announces Anti-CD27 Agonist, an Investigational Anti-Cancer Immunotherapy, Advancing in Collaboration with MSD 465
Oct 18, 2016: Canadian Ebola vaccine enters new trial phase 466
Jun 20, 2016: Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe 467
Jun 15, 2016: Merck Highlights Data on relebactam in combination with imipenem/cilastatin at ASM Microbe 2016 468
Jun 15, 2016: Merck Presents Data on ZERBAXA (ceftolozane and tazobactam) at ASM Microbe 2016 469
May 25, 2016: Cempra Announces Successful Results in the Phase 2 Community Acquired Bacterial Pneumonia (CABP) Trial Conducted by Japanese Partner, Toyama Chemical (a subsidiary of FUJIFILM Holdings Corporation) 470
May 18, 2016: Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference 471
May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference 473
May 12, 2016: Cempra to Present Solithromycin IV Data at ATS 2016 475
May 02, 2016: Ebola vaccine: Promising phase I trials 476
Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference 477
Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Hypertension Research at the Upcoming American Thoracic Society 2016 International Conference 478
Apr 04, 2016: Cempra to Present Data on Solithromycin at ECCMID 479
Feb 01, 2016: Cempra and Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement for Solithromycin 480
Jan 05, 2016: Cempra Doses Initial Patient in Phase 2 Clinical Trial of Solithromycin in NASH 481
Other Significant Developments 482
Oct 09, 2017: Johnson & Johnson investing $350M in EU biologics operation, adding 200 jobs 482
Jun 22, 2017: Merck and Premier Expand Collaboration to Address Chronic Care and Vaccination Rates 483
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Merck 485
Feb 16, 2017: Merck’s Fight Against Infectious Disease Goes Digital with Launch of ILUM Health Solutions 486
Oct 14, 2016: Merck Launches Biosimilars Clarified, a New Online Educational Resource about Biosimilar Medicines for Patients and the Healthcare Community 487
Jun 09, 2016: Menarini Group and MSD Extends Global Partnership to the Asia-Pacific Region 488
Jun 08, 2016: Merck Expands its Investment Fund Merck Ventures 489
Appendix 490
Methodology 490
About GlobalData 490
Contact Us 490
Disclaimer 490

List of Tables
Merck & Co Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 17
Merck & Co Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 18
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 19
Merck & Co Inc, Deals By Therapy Area, 2011 to YTD 2017 20
Merck & Co Inc, Medical Devices Deals, 2011 to YTD 2017 22
Merck & Co Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 23
Hypermarcas To Sell Rights To Manufacture Medicines To MSD Brazil Investments For US$31 Million 39
Adolor Reacquires Rights Of ENTEREG From GlaxoSmithKline 40
Grail Raises USD914 Million in First Tranche of Series B Financing 41
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 43
Just Biotherapeutics Raises USD15 Million in Series A Financing Round 45
RaNA Therapeutics Raises USD55 Million in series B Financing 46
Afferent Pharma Raises USD55 Million in Series C Financing 47
Gladius Pharma Raises USD3.3 Million in Series A Financing 48
NGM Biopharma Raises USD106 Million in Series E Financing 49
EnGene Raises USD11 Million in Series B Venture Financing 50
OsteoQC Raises Funds in Venture Financing 51
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 52
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 53
OncoEthix Raises US$19 Million In Series B Financing 54
Aviir Raises US$20 Million In Venture Financing 56
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding Round 58
cCAM Biotherapeutics Raises US$6 Million In Series A Financing 59
Afferent Pharmaceuticals Secures USD5 Million in Venture Funding 60
Aviir Secures US$10 Million In Venture Financing 61
High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 62
BeiGene Receives Investment From Merck Sharp & Dohme 63
HTG Molecular Raises USD15.7 Million in First Tranche of Series D Financing 64
Antigen Express Enters into Agreement with Merck for KEYTRUDA 65
CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 66
Aeglea BioTherapeutics Enters into Agreement with Merck 67
SELLAS Life Sciences Enters into Clinical Trial Agreement with Merck 68
Eisai Enters into Agreement with Merck for Eribulin 69
Eisai Enters into Agreement with Merck 70
AstraZeneca Enters into Agreement with Merck 71
Invenra Enters into Agreement With Merck 72
PDS Biotech Enters into Agreement with Merck 73
Leap Therapeutics Enters into Agreement with Merck International 74
Aduro Biotech Expands Agreement with Merck 75
OncoSec Medical Enters into Agreement with Merck Sharp & Dohme 76
Array BioPharma Enters into Agreement with Merck 77
Atara Biotherapeutics Enters into Agreement with Merck 78
HitGen Enters into Agreement with Merck 79
BerGenBio Enters into Agreement with Merck 80
Stratophase Enters into Agreement with Merck 81
CMIC Enters into Agreement with MSD for Diazoxide 82
Ramot at Tel Aviv University Enters into Research Agreement with Merck 83
NOXXON Pharma Enters into Agreement with Merck 84
Natrix Separations Enters into Co-Development Agreement with Merck and Sanofi 85
Proteros biostructures Enters into Agreement with Merck Sharp & Dohme 86
Genexine Enters into Clinical Research Agreement with Merck 87
Adaptimmune Therapeutics Enters into Clinical Trial Agreement with Merck for Keytruda 88
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 89
Merck Enters into Distribution Agreement with JenKem Tech 90
MSD Enters into Agreement with Kyorin Pharma 91
Agency for Science, Technology and Research Enters into Agreement with Merck 92
Menarini Asia-Pacific Enters into Agreement with Merck 93
Innovative Targeting Solutions Enters into Research Agreement with Merck 94
Fujifilm Diosynth Biotech Partners with Merck 95
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 96
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 97
Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 98
ImmunoGen Enters into Research Agreement with Merck 99
Merck Enters into Agreement with AbCellera Biologics 100
Affimed Enters into Research Agreement with Merck 101
BioLineRx Enters into Agreement with Merck 102
Quartet Medicine Enters into Agreement with Merck 103
Complix Expands Agreement with Merck 104
Eli Lilly Expands its Agreement with Merck 105
Merck Enters into Agreement with Akeso Biopharma 106
Amgen and Merck Enter into Agreement 107
Viralytics Enters into Agreement with Merck 108
GlaxoSmithKline Partners with Merck 109
Synthace Enters into Agreement with Merck 110
MacroGenics Enters into Agreement with Merck 111
Incyte Extends Partnership with Merck 112
Proteros Enters Into an Agreement with Merck Sharp and Dohme 113
Merck Enters into Agreement with OBI Pharma 114
Merck Enters into Agreement with DNAtrix 115
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 116
Immune Design Enters into Clinical Collaboration Agreement with Merck 117
Laboratorios Farmaceuticos Rovi Enters into Co-Marketing Agreement with Merck Sharp & Dohme for Orvatez 118
Plexxikon Enters into Agreement with Merck 119
PeptiDream Enters into Peptide Discovery Agreement with Merck 120
Organovo Enters into Research Agreement with Merck Sharp & Dohme 121
Astellas Pharma to Enter into Agreement with MSD 122
Syndax Pharma Expands its Agreement with Merck 123
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 124
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 125
Merck Expands Agreement with Eli Lilly 126
Enumeral Biomedical Amends its Agreement with Merck Sharp & Dohme 127
Kyorin Pharma Amends Co-Marketing Agreement with MSD 128
Bind Therapeutics Enters into R&D Agreement with Merck 129
Advaxis Enters into Agreement with Merck 130
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 131
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 132
Merck Enters Into Co-Development Agreement With Samsung Bioepis For MK-1293 133
Dako Enters Into Co-Development Agreement With Merck 134
Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 135
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 136
Optimer Pharma Extends Co-Promotion Agreement With Cubist Pharma For Dificid 138
Abide Therapeutics Enters Into Co-Development Agreement With Merck 139
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 140
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 141
Merck And Samsung Bioepis Enter Biosimilars Development Agreement 142
Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 143
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 144
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 145
ActoGeniX Enters Into Research Agreement With Merck 146
TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 147
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 148
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 149
Redbiotec Extends Drug Discovery Agreement With Merck 151
Merck Forms Joint Venture With Supera Farma Laboratorios 152
MSD Enters Into Distribution Agreement With Julphar 153
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 154
Fundacion Medina Enters Into Research Agreement With Cubist Pharma 155
Chongqing Zhifei Biological Products Extends Co-Marketing Agreement With Merck For RotaTeq 156
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 157
Merck Enters Into Co-Development Agreement With Endocyte For Cancer Drug 158
MSD India Plans Co-Marketing Agreement For Diabetes Drugs 160
Ezose Sciences Enters Into Co-Development Agreement With Merck 161
Vaccine & Gene Therapy Institute Enters Research Agreement With Merck 162
Redbiotec Enters Into Drug Discovery Agreement With Merck 163
Merck Enters Into Co-Development Agreement With Beijing Genomics Institute 164
Merck Enters Into Co-Development Agreement With Serum Institute of India 165
Merck Extends Co-Promotion Agreement With Roche For VICTRELIS 166
Merck Enters Into Co-Promotion Agreement With Daewoong Pharma For Vytorin 167
MSD Enters Into Co-Marketing Agreement With Taiho Pharma For Vorinostat 168
Trius Therapeutics Enters into Agreement with Lawrence Livermore National Laboratory 169
MSD In India Enters Into Co-Marketing Agreement With Sun Pharma 170
Merck Amends Distribution Agreement With Johnson & Johnson 171
International Drug Development Institute Partners with Sanofi Pasteur 173
Optimer Pharma Enters Into Co-Promotion Agreement With Cubist Pharma 174
TPP Global Development Enters Into Agreement With University of Aberdeen 175
ARIAD Announces Co-Promotion Agreement With Merck 176
Lycera Enters Into Research Agreement With Merck 177
Merck Enters Into An Agreement With PAREXEL International 178
Merck Enters into Licensing Agreement with Cue Biopharma 179
Merck Enters into Licensing And Option Agreement with AIMM Therapeutics 180
Urovant Sciences Enters into Licensing Agreement with Merck Sharp & Dohme 181
Merck Enters into Licensing Agreement with Teijin Pharma 182
Kyorin Pharma Enters into Licensing Agreement with Merck 183
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 184
Merck Enters into Licensing Agreement with Cancer Research Technology 185
Adimab Enters into Licensing Agreement with Merck 186
Merck Enters into Licensing Agreement with Selvita 187
Allergan Enters into Licensing Agreement with Merck 188
Merck Enters into Licensing Agreement with BioNovion 189
Zymeworks Extends Licensing Agreement with Merck 190
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 191
ARMO Biosciences Enters into Licensing Agreement with Merck 192
Cerecor Enters Into Licensing Agreement With Merck For MK-0657 193
Merck Enters into Licensing Agreement with Ra Pharma 195
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 197
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 199
Exelixis Enters Into Licensing Agreement With Merck For PI3K-delta 200
Zymeworks Enters into Licensing Agreement with Merck 201
Merck Enters into Licensing Agreement with Moderna Therapeutics 202
Merck Enters into Licensing Agreement with Harvard University 203
Merck Enters into Licensing Agreement with AureoGen Biosciences 204
Merck Enters into Licensing Agreement with Codexis for CodeEvolver Platform Technology 205
Merck Extends Licensing Agreement with Agenus 207
Arvinas Enters into Licensing Agreement with Merck 208
Merck Enters into Licensing Agreement with Medicines Patent Pool 209
Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 210
EnWave Enters into Licensing Agreement with Merck 212
Merck Enters into Licensing Agreement with NewLink Genetics 213
Euroscreen Enters into Licensing Agreement with Merck 215
Sun Pharma Enters into Licensing Agreement with Merck 216
Kyorin Pharma Enters into Licensing Agreement with Merck 217
Bionomics Enters into Licensing Agreement with Merck for BNC375 218
Gulf Pharma Enters into Licensing Agreement with MSD 219
NanoBio Enters Into Licensing Agreement With Merck 220
Nuevolution Enters Into Licensing Agreement With Merck 221
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 222
Merck Expands Licensing Agreement with Ablynx 224
Polyplus-transfection Enters Into Licensing Agreement With Merck 226
AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 227
Depomed Expands Licensing Agreement With Merck For Metformin Patents 229
Bionomics Extends Licensing Agreement with Merck 230
Merck Enters Into Licensing Agreement With Lupin 231
Xencor Enters Into Licensing Agreement With Merck 232
Merck Exercises Option For Licensing Agreement With Xenon Pharma For Cardiovascular Disease Targeted Compounds 233
Hawaii Biotech Enters Into Licensing Agreement With Merck For West Nile Vaccine Technology 234
Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 235
Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 236
Microbiotix Enters Into Licensing Agreement With Merck For MBX-700 And MBX-701 238
Menlo Therapeutics Enters into Licensing Agreement with Merck 239
Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 240
Netherlands Translational Research Center Enters Into Licensing Agreement With Merck 241
Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 242
Delphi Genetics Enters Into Licensing Agreement With Merck For StabyExpress Technology 243
MultiVir Enters into Licensing Agreement with Merck Sharp & Dohme 244
Merck Enters Into Licensing Agreement With Yamasa For EFdA 245
R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 246
Ambrx Enters Into Licensing Agreement With Merck For Site Specific Protein Medicinal Chemistry Technology 247
OncoEthix Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For OTX015 248
Merck Enters Into Licensing Agreement With Numerate For In Silico Drug Design Technology 249
Merck Extends Licensing Agreement with Codexis 250
Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 251
Mochida Pharma Enters Into Licensing Agreement With Merck 252
Bend Research Enters Into Licensing Agreement With Merck 253
Hawaii Biotech Enters Into Licensing Agreement With Merck 254
Merck Enters Into Licensing Agreement With FKD Therapies 255
AbD Serotec Amends Licensing Agreement With Merck 256
Trius Therapeutics Enters Into Licensing Agreement With Bayer HealthCare For Torezolid Phosphate 257
MSD Enters Into Licensing Agreement With Astellas US For vernakalant 258
Hanwha Chemical Enters Into Licensing Agreement With Merck For HD203 259
Hanmi Pharma Expands Licensing Agreement With Merck For Amosartan 260
Bionomics Raises USD9 Million in Private Placement of Shares 261
OpGen Raises USD5 Million in Private Placement of Shares 262
BeiGene Raises USD97.4 Million in Private Placement of Series A-2 Preferred Stock 263
Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 264
BeiGene Raises USD74.5 Million in Private Placement of Series A Preferred Stock 265
Trius Therapeutics Completes Public Offering Of Shares For US$34 Million 266
Trius Therapeutics Completes Second Tranche Of Private Placement Of Shares For US$5 Million 267
VirtualScopics Completes First Tranche Of Private Placement Of Shares For US$3 Million 269
Trius Therapeutics Completes Over-allotment Option Of Underwritten Public Offering For US$52 Million 270
Trius Therapeutics Completes Private Placement Of Units For US$30 Million 272
Merck Raises USD544 Million in Public Offering of 0.5% Notes Due 2024 273
Merck Raises USD544 Million in Public Offering of 1.375% Notes Due 2036 274
Merck Completes Public Offering of Notes Due 2020 for USD1.25 Billion 275
Merck Completes Public Offering of Notes Due 2022 for USD1.25 Billion 277
Merck Completes Public Offering of Notes Due 2020 for USD700 Million 279
Merck Completes Public Offering of Notes Due 2025 for USD2.5 Billion 281
Merck Completes Public Offering of Notes Due 2017 for USD300 Million 283
Merck Completes Public Offering of Notes Due 2045 for USD2 Billion 285
Merck Raises USD1.25 Billion in Public Offering of 1.875% Notes Due 2026 287
Merck Raises USD625 Million in Public Offering of 2.5% Notes Due 2034 289
Merck Raises USD1.25 Billion in Public Offering of 1.125% Notes Due 2021 291
Cubist Pharma Completes Private Placement Of Notes Due 2020 For US$450 Million 293
Cubist Pharma Completes Private Placement Of Notes Due 2018 For US$350 Million 294
Merck Completes Public Offering Of Notes Due 2016 For US$500 Million 295
Merck Completes Public Offering Of Notes Due 2016 For US$1 Billion 297
Merck Completes Public Offering Of Notes Due 2018 For US$1 Billion 299
Merck Completes Public Offering Of Notes Due 2023 For US$1.75 Billion 301
Merck Completes Public Offering Of Notes Due 2043 For US$1.25 Billion 303
Merck Completes Public Offering Of Floating Notes Due 2018 For US$1 Billion 305
BeiGene Raises USD3 Million in Private Placement of Notes 307
Merck Completes Public Offering Of Notes Due 2042 For US$500 Million 308
Merck Completes Public Offering Of 1.1% Notes Due 2018 For US$1 Billion 310
Merck Completes Public Offering Of Notes Due 2022 For US$1 Billion 312
Pharmaron Acquires Hoddesdon UK Site from Merck Sharpe & Dohme 314
Aralez Pharma Acquires US and Canadian rights to Zontivity from Merck 315
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 316
Piramal Enterprises Acquires Five OTC Brands from Organon India and MSD for USD14 Million 317
Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 318
Merial to Acquire Manufacturing Facility from Merck 319
Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck 320
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 322
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 324
KBI Biopharma To Acquire Biologics Operations Of Merck 326
Amphastar Pharmaceuticals Acquires API manufacturing business of Merck 327
Oak Pharma Acquires Tafluprost Business from Merck 328
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 329
Aspen Acquires Portfolio of Drugs from Merck for USD600 Million 330
Forest Labs To Acquire US Marketing Rights To Saphris From Merck Sharp & Dohme For US$240 Million 333
CCS Healthcare To Acquire Propyless From Merck Sharp & Dohme 334
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 335
Cerecor Acquires Rights To COMT Inhibitors From Merck 336
Kyorin Acquires Production Facility from MSD 338
Merck Acquires Rigontec 339
Paratek Pharma May Sell Itself 341
Merck Acquires Afferent Pharma 343
Merck Acquires IOmet Pharma 344
Merck Acquires cCAM Biotherapeutics 345
Merck Acquires Cubist Pharma for USD9.5 Billion 346
Merck Acquires OncoEthix for USD375 Million 348
Merck Completes Acquisition of Idenix Pharma for USD3.9 Billion in cash 349
Alnylam Pharma Acquires Sirna Therapeutics From Merck 351
Akorn Acquires Inspire Pharma From Merck For US$53 Million 353
Cubist Pharma Completes Acquisition Of Optimer Pharma For Up To US$801 Million 355
Cubist Pharma Completes Acquisition Of Trius Therapeutics For Up To US$818 Million In A Tender Offer 357
Telerx Acquires Sentrx Safety Solutions, Pharmacovigilance Outsourcing Company 359
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 360
Merck Plans To Acquire Micro Labs, Maker Of Generic Drugs 362
Cubist Pharma Completes Acquisition Of Adolor For US$415 Million 363
Johnson & Johnson Acquires Johnson & Johnson Merck Consumer Pharma From Merck Sharp & Dohme For US$175 Million 365
Nuvisan Acquires Essex Pharma Development From Merck 366
Merck Completes Acquisition Of Inspire Pharma 367
Fujifilm Completes Acquisition Of MSD Biologics 369
Fujifilm Completes Acquisition Of Diosynth 371
Merck & Co Inc, Key Competitors 372
Merck & Co Inc, Key Employees 373
Merck & Co Inc, Subsidiaries 375
Merck & Co Inc, Joint Venture 397

★海外企業調査レポート[Merck & Co Inc (MRK)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Landmarks Berhad：企業の戦略・SWOT・財務情報
    Landmarks Berhad - Strategy, SWOT and Corporate Finance Report Summary Landmarks Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Genmedica Therapeutics SL-製薬・医療分野：企業M&A・提携分析
    Summary Genmedica Therapeutics SL (Genmedica) is a clinical-stage biopharmaceutical company that researches, discovers and develops orally available NCEs for the treatment of diabetes. The company’s expertise spans in the development of specific, dual-action, small molecule inhibitors that targets b …
  • British Broadcasting Corporation：企業の戦略・SWOT・財務情報
    British Broadcasting Corporation - Strategy, SWOT and Corporate Finance Report Summary British Broadcasting Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Lego AS：企業の戦略的SWOT分析
    Lego AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Takashimaya Company, Limited：企業の戦略・SWOT・財務分析
    Takashimaya Company, Limited - Strategy, SWOT and Corporate Finance Report Summary Takashimaya Company, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Loral Space & Communications Inc. (LORL)：企業の財務・戦略的SWOT分析
    Loral Space & Communications Inc. (LORL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Proserv：石油・ガス：M&Aディール及び事業提携情報
    Summary Proserv is an energy service provider that offers engineering services. The company offers drilling, surface, subsea and decommissioning services. Its subsea services comprise subsea engineering, subsea production equipment and services, subsea components and accessories, subsea production e …
  • The Wharf (Holdings) Limited
    The Wharf (Holdings) Limited - Strategy, SWOT and Corporate Finance Report Summary The Wharf (Holdings) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Ranhill Holdings Berhad (RANHILL)：企業の財務・戦略的SWOT分析
    Ranhill Holdings Berhad (RANHILL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Severoceske doly as：企業の戦略・SWOT・財務情報
    Severoceske doly as - Strategy, SWOT and Corporate Finance Report Summary Severoceske doly as - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Adaptimmune Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Adaptimmune Ltd (Adaptimmune), a subsidiary of Adaptimmune Therapeutics Plc is a clinical stage biotechnology company that develops T-cell therapy products for the treatment of cancer. The company’s pipeline peptides include NY-ESO TCR used to treat cancer cells, MAGE A-10 TCR used for the t …
  • Aptech Ltd (APTECHT)：企業の財務・戦略的SWOT分析
    Aptech Ltd (APTECHT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Zoomlion Heavy Industry Science and Technology Co., Ltd.：企業の戦略・SWOT・財務情報
    Zoomlion Heavy Industry Science and Technology Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Zoomlion Heavy Industry Science and Technology Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the comp …
  • Cosmo Pharmaceuticals NV (COPN)：企業の財務・戦略的SWOT分析
    Summary Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix technology. Its proprietary clinical development pipeline intended for the treatment of …
  • System Dynamics International Incorporated：企業の戦略・SWOT・財務分析
    System Dynamics International Incorporated - Strategy, SWOT and Corporate Finance Report Summary System Dynamics International Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Utah Medical Products Inc (UTMD)：企業の財務・戦略的SWOT分析
    Summary Utah Medical Products Inc (Utah Medical) is a medical device company that offers disposable and reusable products. The company offers blood pressure monitoring and blood management, gynecology, perinatology, urology and electrosurgery, respiratory and OEM products. Its blood pressure monitor …
  • Medigus Ltd (MDGS)：医療機器：M&Aディール及び事業提携情報
    Summary Medigus Ltd (Medigus) is a medical device company that develops minimally invasive endosurgical tools and imaging solutions across medical and industrial applications. The company’s muse system enables endoscopists to treat gastroesophageal reflux disease (GERD) by performing fundoplication …
  • Jiangsu Jumpcan Pharmaceutical Group Co Ltd (600566)：製薬・医療：M&Aディール及び事業提携情報
    Summary Jiangsu Jumpcan Pharmaceutical Group Co Ltd (Jiangsu Jumpcan Pharma) is a developer, manufacturer and distributor of Chinese traditional medicine, Western medicine, daily use chemicals and healthcare products. The company offers its products in various therapeutic segments such as detoxifica …
  • Victek Co., Ltd.：企業の戦略・SWOT・財務情報
    Victek Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Victek Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • ALS Ltd (ALQ)：石油・ガス：M&Aディール及び事業提携情報
    Summary ALS Limited (ALS), formerly, Campbell Brothers Limited is a diversified testing service provider. The company provides testing services in the areas of minerals, life sciences, energy and industrial. It provides offers chemical and laboratory services, technical testing and inspection servic …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆